Showing 5441-5450 of 8687 results for "".
- Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/cemiplimab-receives-fda-breakthrough-therapy-designation-for-advanced-cutaneous-squamous-cell-carcinoma/2458063/The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC. Cemiplimab is an
- Deion Sanders Named Brand Ambassador for Botox Cosmetichttps://practicaldermatology.com/news/deion-sanders-named-brand-ambassador-for-botox-cosmetic/2458062/NFL analyst and philanthropist Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, is the new brand ambassador for BOTOX® Cosmetic. Allergan also released two vide
- Galderma Names New Managers of Prescription Business and Aesthetic & Corrective Business Units; Dr. Kelly Huang to Obalonhttps://practicaldermatology.com/news/alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit-dr-kelly-huang-to-obalon/2458064/Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask <
- Dermira Presents New Data on Late-Stage Programs at European Dermatology Congresshttps://practicaldermatology.com/news/dermira-presents-new-data-on-late-stage-programs-at-european-dermatology-congress/2458066/Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Geneva, Switzerland, September 13&
- RXI Completes Enrollment of Phase 2 Study of Samcyprone for Cutaneous Wartshttps://practicaldermatology.com/news/rxi-completes-enrollment-of-phase-2-study-of-samcyprone-for-cutaneous-warts/2458067/RXi Pharmaceuticals Corporation completed enrollment in its Phase 2 clinical trial, RXI-SCP-1502, with Samcyprone™for the clearance of cutaneous warts. Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopr
- Skin Color Affects Skin Sensitivity to Heat and Mechanical Stimulihttps://practicaldermatology.com/news/skin-color-affects-skin-sensitivity-to-heat-and-mechanical-stimuli/2458069/Researchers at the Bluestone Center for Clinical Research at the New York University College of Dentistry (NYU Dentistry) have identified a novel molecular mechanism which explains why dark-skinned and light-skinned people respond differently to heat and mechanical stimulation. In a study
- Kyocera Begins Research in AI-based Image Recognition to Help Diagnose Skin Diseases and Cancers Via Smartphonehttps://practicaldermatology.com/news/kyocera-begind-research-in-ai-based-image-recognition-to-help-diagnose-skin-diseases-and-cancers-via-smartphone/2458070/Kyocera Corporation is partnering with the University of Tsukuba to develop Artificial Intelligence (AI)-based image recognition for eHealth applications to diagnose melanoma and other skin diseases by analyzing digital images of a patient’s skin.
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- Colorescience Takes Aim at Rosacea with All Calm™ Clinical Redness Correctorhttps://practicaldermatology.com/news/colorescience-takes-aim-at-rosacea-with-all-calm-clinical-redness-corrector/2458082/Colorescience® is introducing All Calm™ Clinical Redness Corrector. Available Colorescience.com, all Calm Clinical Redness Corrector helps neutralize redness with its subtle green undertones. The patent-pending BioSolaceTM complex
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr